-transparent.png){kind=logo}
Cytomegalovirus (CMV) infection is the most frequent cause of lethal infection after bone marrow transplantation. Viremia occurs in 50% of patients seropositive for CMV before transplantation. Interstitial pneumonitis due to CMV occurs in 10% to 20% of patients with 85% mortality. It is known that CMV infection is due to host reactivation of latent CMV infection or to the transmission of the virus by the marrow donor or by blood transfusions. Treatment of CMV infection has been disappointing in the past. All attempts to treat CMV pneumonia with available agents have failed. Recent studies have indicated the usefulness of prophylactic measures and the early treatment of CMV infections. The use of hyperimmune gammaglobulins has given contradictory results. The selection of seronegative marrow donors or blood donors is useful only if the recipient is seronegative. New antiviral drugs have been used recently in preliminary clinical trials. In preliminary studies a guanosine analogue similar to Acyclovir (DHPG Synthex or BWB 759 U Wellcome) has given reasonable hope of disease cure if it is used early before the occurrence of pneumonia. Phosphonoformate (Foscarnet) has also been shown to be active against CMV infection. Both drugs have good antiviral and clinical action in immunosuppressed patients but the results have been disappointing in cases of pneumonia. Relapse occurs frequently after cessation of the treatment and attempts are being made to use maintenance therapy.
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
December 1987,
Journal of medical virology,
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
March 1975,
La Nouvelle presse medicale,
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
June 1984,
Revue francaise de transfusion et immuno-hematologie,
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
September 1988,
Pathologie-biologie,
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
June 1984,
Revue francaise de transfusion et immuno-hematologie,
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
January 1990,
Reviews of infectious diseases,
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
January 1994,
Gastroenterologie clinique et biologique,
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
April 1989,
Medicina clinica,
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
January 2003,
Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti,
E Gluckman, and
McMazeron, and
H Keable, and
J Meletis, and
D Bombail, and
I Jolivet, and
J J Huart, and
T Nebout, and
M Cavazzana, and
H De Castro
September 1990,
Nihon rinsho. Japanese journal of clinical medicine,
